logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Nixes Expanded Dacogen Use : Astex Pharma

FDA Nixes Expanded Dacogen Use : Astex Pharma

Astex Pharmaceuticals Inc. (ASTX: Quote) announced Tuesday that the FDA has declined to approve Dacogen for Injection in the additional indication of acute myeloid leukemia in elderly patients who are not considered candidates for induction therapy.

Dacogen is currently approved for the treatment of myelodysplastic syndrome, which is a disease of the blood and bone marrow, and is available in more than 30 countries worldwide including, key markets such as the United States, Brazil, China, India, Russia and Turkey.

Dacogen was licensed by Astex Pharma to MGI Pharma Inc., in August 2004, which in turn, sub-licensed the drug to Janssen-Cilag, a Johnson & Johnson company in July 2006. MGI Pharma was acquired by Eisai Corp of North America in January 2008.

The supplemental New Drug Application for Dacogen for patients with acute myeloid leukemia in adults 65 years of age or older who are not considered candidates for induction therapy, which was submitted by Eisai, was based on a phase III clinical trial (DACO-016) data.

An FDA panel, which reviewed the application, voted 10 to 3 against the new use for Dacogen last month, saying that the drug did not have a favorable benefit-risk profile in the acute myeloid leukemia setting.

In line with the panel's recommendations, the FDA has also declined to approve Dacogen for additional use on the grounds that the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over the control arm.

The proposal for Dacogen's approval for the treatment of elderly Acute Myeloid Leukemia is under review in the European Union, and the European Medicines Agency is expected to announce its decision later this year.

ASTX closed Tuesday's trading at $1.83, down 4.19%, on a volume of 571,232 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
'Booth babes' will not be seen at the RSA Conference scheduled to be held next month, as the exhibitors have added a new clause to its rules that ban revealing clothes. Although, RSA did not use the term "booth babe," its contract clearly explains that staff deployed at booths should wear business... Election fever has gripped the UK as Prime Minister David Cameron on Monday urged his people to prudently choose either a prosperous future under his Conservative Party or economic ruin under the Labour Party headed by Ed Miliband. Fast food giant McDonald's Corp. (MCD), reportedly plans to serve its breakfast menu for the whole day. According to a CNBC report citing analysts from Janney Capital Markets, McDonald's is planning to test serve breakfast for the whole day at select locations starting in the next few months. "Our...
comments powered by Disqus
Follow RTT